Aurinia Pharmaceuticals (TSE:AUP) (NASDAQ:AUPH) will post its quarterly earnings results after the market closes on Thursday, November 8th. Analysts expect Aurinia Pharmaceuticals to post earnings of C($0.23) per share for the quarter.
Aurinia Pharmaceuticals (TSE:AUP) (NASDAQ:AUPH) last issued its quarterly earnings results on Thursday, August 9th. The company reported C($0.25) EPS for the quarter, missing the consensus estimate of C($0.21) by C($0.04). The business had revenue of C$0.04 million for the quarter, compared to analysts’ expectations of C$0.07 million.
Shares of TSE:AUP opened at C$7.50 on Tuesday. Aurinia Pharmaceuticals has a one year low of C$5.68 and a one year high of C$8.65.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
Further Reading: What is a stock split?